You are here: Home » Current Affairs » Coronavirus » News
Business Standard

Doctors shouldn't practice unethical, unscientific Covid treatment: Dr Kang

Kang is a top virologist

Gagandeep Kang | Coronavirus


Gagandeep Kang
Dr Gagandeep Kang | File photo

India's top virologist, Dr has called the prescription of monoclonal antibody therapy by the doctors in the private hospitals of the country for the treatment of Omicron variant of COVID-19 patients "unethical, immoral and unscientific" and asked the medical fraternity to "practice better medicine than this".

Notably, monoclonal antibodies treatment for COVID has been excluded in the revised National COVID task force treatment.

In a series of tweets, Dr Kang said that she received a call from a 90-year-old diabetic patient from Chennai who narrated to her that he was advised admission to the hospital for the antibody treatment because he was in contact with someone who tested positive for SARS-CoV2.

"A call from a 90-year diabetic uncle in Chennai who said he has advised admission to hospital and antibody treatment because he was in contact with someone who tested positive for SARS-CoV2 sparked this thread," she Dr Kang tweeted.

"We know that 90 per cent or greater infections are currently Omicron in Indian cities. We know that the licensed monoclonal antibody products in India do not neutralise omicron. Yet doctors in private hospitals are prescribing monoclonal antibody therapy (and admission)," she added in her tweet.

The Doctor further pointed out that there is little data in India which is why we do not know if the percentage of vaccinated elderly with Omicron will progress.

"Please remember that even among clinical vulnerable, most contacts will stay asymptomatic or have mild symptoms & recover. Small no. develop severe illness (in India, we have little data so we do not know whether 5% or 20% of vaccinated elderly with omicron will progress)," she tweeted.

"In any case, all the ones who would have gotten better anyway will do fine--but having given antibodies, doctors will ascribe that to their treatment and the hospitals will laugh all the way to the bank. The argument I hear from well-meaning doctors (thankfully not infectious disease specialists) is that it is only one lakh and my patient can afford to buy it, so why not?" Dr Kang said in the tweet.

Dr Kang said that it is unethical, immoral and unscientific to provide the antibodies treatment and asked the doctors to practise better medicine.

"Why not? It is unethical, immoral and unscientific. Surely, as doctors, we can teach and practice better medicine than this. And as patients, please ask for what each drug is expected to do and the evidence to back that up," Dr Kang said.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Mon, January 24 2022. 06:38 IST